Condition: Mycosis Fungoides · Lymphomatoid Papulosis · Sezary Syndrome · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
This description comes directly from the study's public registry record.
Alison Moskowitz, MD · 646-608-3726 · moskowia@mskcc.org
Patricia Myskowski, MD · 646-608-2351
Always discuss trial participation with your own doctor first.
| Stanford University Medical Center | Stanford, California, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Commack | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester | East White Plains, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03587844